Coffee effectively attenuates impaired attention in ADORA2A C/C-allele carriers during chronic sleep restriction.

Diego M Baur, Denise Lange, Eva-Maria Elmenhorst, David Elmenhorst, Andreas Bauer, Daniel Aeschbach, Hans-Peter Landolt

Journal: Progress in neuro-psychopharmacology & biological psychiatry 2022;109():110232

PMID: 33373678

Abstract

Many people consume coffee to attenuate increased sleepiness and impaired vigilance and attention due to insufficient sleep. We investigated in genetically caffeine sensitive men and women whether 'real world' coffee consumption during a simulated busy work week counteracts disabling consequences of chronically restricted sleep. We subjected homozygous C-allele carriers of ADORA2A (gene encoding adenosine A receptors) to five nights of only 5 h time-in-bed. We administered regular coffee (n = 12; 200 mg caffeine at breakfast and 100 mg caffeine after lunch) and decaffeinated coffee (n = 14) in double-blind fashion on all days following sleep restriction. At regular intervals four times each day, participants rated their sleepiness and performed the psychomotor vigilance test, the visual search task, and the visuo-spatial and letter n-back tasks. At bedtime, we quantified caffeine and the major caffeine metabolites paraxanthine, theobromine and theophylline in saliva. The two groups did not differ in age, body-mass-index, sex-ratio, chronotype and mood states. Subjective sleepiness increased in both groups across consecutive sleep restriction days and did not differ. By contrast, regular coffee counteracted the impact of repeated sleep loss on sustained and selective attention, as well as executive control when compared to decaffeinated coffee. The coffee also induced initial or transient benefits on different aspects of baseline performance during insufficient sleep. All differences between the groups disappeared after the recovery night and the cessation of coffee administration. The data suggest that 'real world' coffee consumption can efficiently attenuate sleep restriction-induced impairments in vigilance and attention in genetically caffeine sensitive individuals. German Clinical Trial Registry: # DRSK00014379.

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Address: Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland; Sleep & Health Zurich, University Center of Competence, University of Zurich, Zurich, Switzerland.; Department of Sleep and Human Factors, Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany.; Department of Sleep and Human Factors, Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany; Institute for Occupational and Social Medicine, RWTH Aachen University, Aachen, Germany.; Institute of Neuroscience and Medicine, Forschungszentrum Jülich, Jülich, Germany; Faculty of Medicine, University of Bonn, Bonn, Germany.; Institute of Neuroscience and Medicine, Forschungszentrum Jülich, Jülich, Germany.; Department of Sleep and Human Factors, Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany; Faculty of Medicine, University of Bonn, Bonn, Germany.; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland; Sleep & Health Zurich, University Center of Competence, University of Zurich, Zurich, Switzerland. Electronic address: [email protected].

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.